Hello – When central banks, retail investors and industry all clamor for the same metal, prices don’t just rise—they can launch. Our 2026 Gold Forecast: A Perfect Storm for Demand explains why spot gold could break past $4,000 this year and provides guidance on how to position yourself before it happens. Inside, you’ll discover: -
Why net-buying by central banks just hit a record first-half total, led by Turkey and India. -
How rate cuts and a weakening dollar create a powerful tailwind for precious metals. -
Three practical ways to add gold—from physical bars to high-margin mining stocks paying dividends. -
Price targets suggest $4,000 per ounce if current trends persist. This concise PDF outlines the catalysts, risks, and tactics so you can decide whether to hold the metal, own the miners, or both. 👉 Download your free Gold Forecast now. No cost. No credit card. Just actionable research before the crowd sees the signal. To your investing edge, Matthew Paulson
Founder & CEO, MarketBeat P.S. Only about 2–5 % of investors own physical gold today. If the other 95% start buying, you’ll want to be in first. Grab the report now while it’s still free.
Exclusive Story from MarketBeat High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026Reported by Nathan Reiff. Article Published: 1/19/2026. 
Summary - Three biotech names with promising clinical trial data and a history of revenue generation stand out from the broader field for 2026.
- Atai Beckley and Evommune have promising pipelines focused on mental health disorders and inflammatory disease treatments, respectively.
- CorMedix has proven success with its catheter lock products and is expanding beyond the hemodialysis space in compelling ways.
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, optimize molecules, and make predictions about trial outcomes. Alongside the continued proliferation of technology within drug development, companies focused on obesity, rare diseases, and oncology posted commercial achievements. Heading into 2026, the landscape may reward investors willing to accept a bit more risk. Lower interest rates and improved funding conditions could drive further investment in biotechs, particularly in companies with clear paths to commercialization. Many of the standout biotech stocks to watch in 2026 have tangible catalysts that could drive growth. Major Mental Health Disorder Treatment Potential for Atai Beckley A growing number of investors are paying attention to developments around private space companies and potential future public listings.
In a recent briefing, one research publisher outlines how some investors are seeking early exposure to the space economy through publicly traded assets — without waiting for a formal IPO. The presentation walks through the structure, risks, and mechanics behind this approach for those who want to understand how it works. Read the full sponsor briefing here Atai Beckley (NASDAQ: ATAI) develops therapies for mental health disorders, including treatment-resistant depression (TRD) and substance use disorders. Shares of this penny stock rose about 175% over the last year, despite tapering off somewhat in the final weeks of 2025. Fueling investor interest in recent quarters was the completion of the combination of atai Life Sciences and Beckley Psytech, along with a redomiciliation to the United States. Investors should watch Atai Beckley's BPL-003, a nasal spray in development for TRD and alcohol use disorder. It produced positive topline results in a Phase 2b trial last July and showed additional promising data in November. A Phase 3 trial is likely to start in the second quarter of 2026. The company's pipeline is sizable and also includes other TRD candidates and a potential treatment for social anxiety disorder. ATAI's clinical momentum and a potentially large addressable market are encouraging, but the company must manage high R&D expenses and minimal revenue. For that reason, 2026 could be a make-or-break year. Investors willing to take a chance on a promising TRD treatment may reap substantial rewards, but the stock carries significant risk. Hemodialysis Wins and Broadening Into New Spaces Could Drive CorMedix This Year We've previously highlighted CorMedix Inc. (NASDAQ: CRMD) for its strength in the catheter lock market, as its DefenCath has shown potential to reduce catheter-related infections and hospitalizations among dialysis patients. The company's other notable asset is REZZAYO, a treatment for candidemia currently in a Phase 3 trial, with data expected next quarter. CorMedix is also expanding beyond its core hemodialysis business. The recent acquisition of Melinta Therapeutics, known for fungal and bacterial infection treatments, broadened the company's portfolio and helped boost sales by about $13 million in September alone. Investors may see another lift when the company reports full-year results. The firm's impressive third-quarter 2025 results—including solid top- and bottom-line performance—and a strong cash position should help provide a buffer as healthcare reimbursements face uncertainty in the new year. That may be reflected in the consensus price target for CRMD of $17.86, roughly 153% above current levels. Big Potential in the Atopic Dermatitis Space for New Entrant Evommune With a focus on chronic inflammatory diseases, Evommune (NYSE: EVMN) is the newest biotech on this list to go public. Shares debuted via IPO in November 2025 and have climbed about 14% in their first two months of trading. Because Evommune is recently public, investors have less historical context than for the other companies here, but there are reasons to expect 2026 could be a breakthrough year. In the third quarter of 2025—the only quarterly report Evommune has issued since going public—the company highlighted key Phase 2 readouts for EVO756 and EVO301, aimed at chronic inducible urticaria and certain types of atopic dermatitis, respectively. Top-line results from both trials are expected in the first part of this year and could serve as significant catalysts. Evommune has maintained a modest but healthy cash position, reaching $76 million by the end of the third quarter, and has begun generating revenue through a licensing agreement in Japan. R&D expenses are likely to remain elevated. Analysts are optimistic on EVMN, projecting roughly 84% upside from current levels.
| 
Post a Comment
Post a Comment